Results 161 to 170 of about 2,385 (197)
Some of the next articles are maybe not open access.
Current opinion in investigational drugs (London, England : 2000), 2002
AstraZeneca is developing the P2T (P2YADP) purinoceptor antagonist and platelet aggregation inhibitor, cangrelor, for the potential treatment of unstable angina and as an ultrafast-acting intravenous antithrombotic agent. It is in phase IIb clinical trials [315723]. NDA and MAA applications are planned for after 2003 [275466], [314472].
openaire +1 more source
AstraZeneca is developing the P2T (P2YADP) purinoceptor antagonist and platelet aggregation inhibitor, cangrelor, for the potential treatment of unstable angina and as an ultrafast-acting intravenous antithrombotic agent. It is in phase IIb clinical trials [315723]. NDA and MAA applications are planned for after 2003 [275466], [314472].
openaire +1 more source
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention
JACC: Cardiovascular Interventions, 2023Francesco Franchi +2 more
exaly
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor
JACC: Cardiovascular Interventions, 2023Francesco Franchi +2 more
exaly
Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention
American Heart Journal, 2021Charan Yerasi +2 more
exaly